Angelman综合征患者癫痫发作药物治疗的研究进展
Research Progress on Drug Treatment of Epileptic Seizures in Patients with Angelman Syndrome
DOI: 10.12677/jcpm.2026.53205, PDF,   
作者: 赵 娜, 史雷敏, 岳亚非：西安医学院研究生院，陕西 西安；郭向阳*：陕西省人民医院儿童保健科，陕西 西安
关键词: Angelman综合征；UBE3A；癫痫；左乙拉西坦；氯巴占；Angelman Syndrome； UBE3A； Epilepsy； Levetiracetam； Clobazam
摘要: Angelman综合征(AS)，也叫天使综合征，患者会在儿童期发生难治性癫痫发作，发生率高达90%，本文回顾了AS的癫痫发生机制与癫痫表型，系统总结了现有抗癫痫药物的治疗效用，左乙拉西坦和氯巴占是最常用的抗癫痫药物(Anti-seizure medications, ASMs)，并展望了未来的精准治疗方案，分子疗法的发展为癫痫发作的精准治疗带来了希望。
Abstract: Angelman syndrome (AS), causes severe and refractory epileptic seizures in children, with an incidence rate as high as 90%. This article reviews the epilepsy pathogenesis and epileptic phenotypes of AS, systematically summarizes the therapeutic efficacy of existing anti-epileptic drugs, levetiracetam and clonazepam are the most commonly used anti-epileptic medications (Anti-seizure medications, ASMs), and looks forward to future precise treatment plans. The development of molecular therapies brings hope for precise treatment of epileptic seizures.
文章引用：赵娜, 史雷敏, 岳亚非, 郭向阳. Angelman综合征患者癫痫发作药物治疗的研究进展[J]. 临床个性化医学, 2026, 5(3): 253-262. https://doi.org/10.12677/jcpm.2026.53205

参考文献

[1] Keary, C.J. and McDougle, C.J. (2023) Current and Emerging Treatment Options for Angelman Syndrome. Expert Review of Neurotherapeutics, 23, 835-844. [Google Scholar] [CrossRef] [PubMed]
[2] Manssen, L., Krey, I., Gburek-Augustat, J., et al. (2025) Precision Medicine in Angelman Syndrome. Neuropediatrics, 56, 69-82. http://www.thieme-connect.de/DOI/DOI?10.1055/a-2399-0191 [Google Scholar] [CrossRef] [PubMed]
[3] Samanta, D. (2021) Epilepsy in Angelman Syndrome: A Scoping Review. Brain and Development, 43, 32-44. [Google Scholar] [CrossRef] [PubMed]
[4] Fedak Romanowski, E.M., McNamara, N.A., Neil, E.E., Gottlieb-Smith, R. and Dang, L.T. (2021) Seizure Rescue Medications for Out-Of-Hospital Use in Children. The Journal of Pediatrics, 229, 19-25. [Google Scholar] [CrossRef] [PubMed]
[5] 孙磊, 林卫红. 非惊厥性癫痫持续状态的研究进展[J]. 中风与神经疾病杂志, 2025, 42(8): 711-717, 770.
[6] 斯琴呼. 甲泼尼龙联合丙戊酸钠治疗癫痫患儿的效果研究[J]. 大医生, 2025, 10(14): 26-28.
[7] 刘亚楠, 杨清成, 兰天, 等. 左乙拉西坦与丙戊酸钠二线治疗非惊厥性癫痫持续状态的效果比较[J]. 中国实用医刊, 2025, 52(14): 74-77.
[8] Reiter, L.T. (2023) How Late Is Too Late for Treatment? eLife, 12, e86117. [Google Scholar] [CrossRef] [PubMed]
[9] Tan, W. and Bird, L.M. (2016) Pharmacological Therapies for Angelman Syndrome. Wiener Medizinische Wochenschrift, 167, 205-218. [Google Scholar] [CrossRef] [PubMed]
[10] Buonfiglio, D., Hummer, D.L., Armstrong, A., Christopher Ehlen, J. and DeBruyne, J.P. (2020) Angelman Syndrome and Melatonin: What Can They Teach Us about Sleep Regulation. Journal of Pineal Research, 69, e12697. [Google Scholar] [CrossRef] [PubMed]
[11] Bobylova, M.Y., Mukhin, K.Y., Kuzmich, G.V., Glukhova, L.Y. and Pylayeva, O.A. (2022) Epilepsy in Angelman syndrome. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 122, 100-105. [Google Scholar] [CrossRef] [PubMed]
[12] Tsagkaris, C., Papakosta, V., Miranda, A.V., Zacharopoulou, L., Danilchenko, V., Matiashova, L., et al. (2020) Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors. Current Gene Therapy, 19, 359-366. [Google Scholar] [CrossRef] [PubMed]
[13] Du, X.N., Wang, J. and Wang, Y. (2023) Diagnosis and Treatment of Angelman Syndrome. Chinese Journal of Pediatrics, 61, 667-669. (In Chinese)
[14] Gilmore, R.B., Gorka, D., Stoddard, C.E., Sonawane, P., Cotney, J. and Chamberlain, S.J. (2024) Generation of Isogenic Models of Angelman Syndrome and Prader-Willi Syndrome in CRISPR/Cas9-Engineered Human Embryonic Stem Cells. PLOS ONE, 19, e0311565. [Google Scholar] [CrossRef] [PubMed]
[15] Duis, J., Nespeca, M., Summers, J., Bird, L., Bindels‐de Heus, K.G.C.B., Valstar, M.J., et al. (2022) A Multidisciplinary Approach and Consensus Statement to Establish Standards of Care for Angelman Syndrome. Molecular Genetics & Genomic Medicine, 10, e1843. [Google Scholar] [CrossRef] [PubMed]
[16] Milazzo, C., Mientjes, E.J., Wallaard, I., Rasmussen, S.V., Erichsen, K.D., Kakunuri, T., et al. (2021) Antisense Oligonucleotide Treatment Rescues UBE3A Expression and Multiple Phenotypes of an Angelman Syndrome Mouse Model. JCI Insight, 6, e145991. [Google Scholar] [CrossRef] [PubMed]
[17] Du, X., Wei, L., Yang, B., Long, S., Wang, J., Sun, A., et al. (2023) Cortical and Subcortical Morphological Alteration in Angelman Syndrome. Journal of Neurodevelopmental Disorders, 15, Article No. 7. [Google Scholar] [CrossRef] [PubMed]
[18] Pandya, N.J., Wang, C., Costa, V., Lopatta, P., Meier, S., Zampeta, F.I., et al. (2021) Secreted Retrovirus-Like Gag-Domain-Containing Protein PEG10 Is Regulated by UBE3A and Is Involved in Angelman Syndrome Pathophysiology. Cell Reports Medicine, 2, Article ID: 100360. [Google Scholar] [CrossRef] [PubMed]
[19] Samanta, D. (2022) A Scoping Review on Cannabidiol Therapy in Tuberous Sclerosis: Current Evidence and Perspectives for Future Development. Epilepsy & Behavior, 128, Article ID: 108577. [Google Scholar] [CrossRef] [PubMed]
[20] Godler, D.E., Singh, D. and Butler, M.G. (2024) Genetics of Prader-Willi and Angelman Syndromes: 2024 Update. Current Opinion in Psychiatry, 38, 95-100. [Google Scholar] [CrossRef] [PubMed]
[21] Yamada, M., Okuno, H., Okamoto, N., Suzuki, H., Miya, F., Takenouchi, T., et al. (2022) Diagnosis of Prader-Willi Syndrome and Angelman Syndrome by Targeted Nanopore Long-Read Sequencing. SSRN Electronic Journal, 66, Article ID: 104690.
https://www.sciencedirect.com/science/article/pii/S1769721222002713?via%3Dihub
[22] Lee, D., Chen, W., Kaku, H.N., et al. (2022) Antisense Oligonucleotide Therapy Rescues Disturbed Brain Rhythms and Sleep in Juvenile and Adult Mouse Models of Angelman Syndrome. eLife, 12, e81892.
[23] Pearson, E., Wilde, L., Heald, M., Royston, R. and Oliver, C. (2019) Communication in Angelman Syndrome: A Scoping Review. Developmental Medicine & Child Neurology, 61, 1266-1274. [Google Scholar] [CrossRef] [PubMed]
[24] Gu, B., Zhu, M., Glass, M.R., Rougié, M., Nikolova, V.D., Moy, S.S., et al. (2019) Cannabidiol Attenuates Seizures and EEG Abnormalities in Angelman Syndrome Model Mice. Journal of Clinical Investigation, 129, 5462-5467. [Google Scholar] [CrossRef] [PubMed]
[25] Ebrat Mancilla, E., Sánchez Aparicio, A., Pérez de Vargas Martínez, A., Marín Serrano, M.E., Vaquero Martínez, M., Iglesias Escalera, G., et al. (2024) Epilepsia en el síndrome de Angelman y hallazgos electroencefalográficos más frecuentes. Revista de Neurología, 79, 223-228. [Google Scholar] [CrossRef] [PubMed]
[26] 郭卫杰. 唑尼沙胺辅助治疗癫痫患者的有效性及安全性研究[J]. 临床医药文献电子杂志, 2024, 11(6): 60-62, 46.
[27] 王颖慧, 王丽. 抗癫痫新药的治疗药物监测进展[J]. 儿科药学杂志, 2010, 16(3): 51-54.
[28] 朱娜, 高庆武, 董方梅. 天使综合征儿童陪伴辅助机器人设计[J]. 工业设计, 2025(03): 51-54.
[29] 中华人民共和国国家卫生健康委员会. 天使综合征[J]. 中国实用乡村医生杂志, 2019, 26(12): 2-4.
[30] 李惠, 张永会, 柴光德. 天使综合征患者诊疗体会及回顾性分析[J]. 国际临床研究杂志, 2024, 8(11): 104-107.
[31] 万丽君, 刘学伍. 新型抗癫痫发作药物布瓦西坦作用机制及临床研究进展[J]. 中风与神经疾病杂志, 2024, 41(6): 507-510, 577.
[32] 刘泰麟, 肖农. 拉考沙胺治疗儿童癫痫的有效性和安全性研究进展[J]. 临床医学进展, 2025, 15(5): 919-930.
[33] 邬天月, 陈红玲, 刘占利, 等. 第三代抗癫痫药物治疗儿童难治性癫痫的研究进展[J]. 中国处方药, 2025, 23(8): 117-122.
[34] 宫玉哲, 王天成. Lennox-Gastaut综合征治疗研究进展[J]. 医学综述, 2020, 26(9): 1802-1807.
[35] 李敏, 凌涛. 基于FAERS数据库的芳香族抗癫痫药物相关SJS/TEN真实世界研究[J]. 实用药物与临床, 2025, 28(11): 832-837.
[36] 谢婧, 向秋蒙, 贾清艳, 等. 卢非酰胺, 氯巴占和大麻二酚儿童抗癫痫的安全性评价[J]. 儿科药学杂志, 2025, 31(5): 34-39.